EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy

Background and study aims  The US FDA recently approved a cancer treatment with pembrolizumab based upon the tumor biomarker status of deficient mismatch repair (dMMR) rather than a specific disease-based approach. We sought to determine if endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Endosc Int Open
Auteurs principaux: Gleeson, Ferga C., Levy, Michael J., Roden, Anja C., Boardman, Lisa A., Sinicrope, Frank A., McWilliams, Robert R., Zhang, Lizhi
Format: Artigo
Langue:Inglês
Publié: © Georg Thieme Verlag KG 2018
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175678/
https://ncbi.nlm.nih.gov/pubmed/30302387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/a-0650-4447
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires